Biogen says MS Patient on Tecfidera who developed PML suffered longterm lymphopenia
This article represents the opinions, thoughts, and experiences of the author; none of this content has been paid for by any advertiser. The MultipleSclerosis.net team does not recommend or endorse any products or treatments discussed herein. Learn more about how we maintain editorial integrity here.
- Biogen Idec Third Quarter 2014 Revenues Increase 37% to $2.5 Billion [press release]. October 22, 2014. http://www.biogenidec.com/press_release_details.aspx?ID=14712&Action=1&NewsId=2400&PID=61997
- Biogen shares drop after report of patient while on Tecfidera. Don Seiffert, Boston Business Journal. October 22, 2014. http://www.bizjournals.com/boston/blog/bioflash/2014/10/biogen-shares-drop-after-report-of-death-of.html
- Biogen shares fall after Tecfidera patient dies. Meg Tirrell, CNBC. October 22, 2014. http://www.cnbc.com/id/102110717
- Biogen Says Death of MS Patient Not Related to Drug. Jonathan Rockoff, Wall Street Journal. October 7, 2013. http://online.wsj.com/articles/SB10001424052702303442004579121511814676436